{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:16:17Z","timestamp":1792264577174,"version":"4.4.0"},"reference-count":121,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>In recent years, the published literature has suggested the key involvement of the cytokine interleukin-31 (IL-31) in the symptomatology of pruritus, and both IL-31 and its receptor have become potential therapeutic targets for a range of pruritic diseases. Elevated levels of IL-31 or its receptor have been reported in the tissue or serum of patients with pruritic skin diseases, such as atopic dermatitis, prurigo nodularis, and psoriasis. Pruritus places a heavy burden on patients, and can have a negative impact on daily life, sleep, and mental health. Since current anti-pruritic treatments are often ineffective, affected patients are in urgent need of new therapies. As a result, drug development targeting the IL-31 pathway is evolving rapidly. To date, only nemolizumab, a humanized monoclonal antibody targeting the IL-31 receptor, has successfully completed late-stage clinical studies. This article will highlight our current clinical understanding of the role of IL-31 in pruritic disease, and explore recent progress in drug development as well as the anticipated future advances in this field.<\/jats:p>","DOI":"10.3389\/fmed.2021.638325","type":"journal-article","created":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T18:09:32Z","timestamp":1613239772000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":106,"title":["Interleukin-31 as a Clinical Target for Pruritus Treatment"],"prefix":"10.3389","volume":"8","author":[{"given":"Kenji","family":"Kabashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Irie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/ni1084","article-title":"Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice","volume":"5","author":"Dillon","year":"2004","journal-title":"Nat Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jaci.2016.02.020","article-title":"The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves","volume":"138","author":"Feld","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.22034\/IJI.2019.80253","article-title":"Pathogenesis of atopic dermatitis: current paradigm","volume":"16","author":"Furue","year":"2019","journal-title":"Iran J Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jaci.2011.10.042","article-title":"IL-31 regulates differentiation and filaggrin expression in human organotypic skin models","volume":"129","author":"Cornelissen","year":"2012","journal-title":"J Allergy Clin Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cytogfr.2008.08.003","article-title":"Structures and biological functions of IL-31 and IL-31 receptors","volume":"19","author":"Zhang","year":"2008","journal-title":"Cytokine Growth Factor Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1684\/ejd.2010.1196","article-title":"Increased expression of mRNAs for IL-4, IL-17, IL-22 and IL-31 in skin lesions of subacute and chronic forms of prurigo","volume":"21","author":"Park","year":"2011","journal-title":"Eur J Dermatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1177271920940712","DOI":"10.1177\/1177271920940712","article-title":"Interleukin-31 and chronic pruritus of unknown origin","volume":"15","author":"Salao","year":"2020","journal-title":"Biomark Insights."},{"key":"B8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2147\/CCID.S257647","article-title":"IL-33\/13 axis and IL-4\/31 axis play distinct roles in inflammatory process and itch in psoriasis and atopic dermatitis","volume":"13","author":"Bodoor","year":"2020","journal-title":"Clin Cosmet Investig Dermatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/vde.12280","article-title":"IL-31-induced pruritus in dogs: a novel experimental model to evaluate anti-pruritic effects of canine therapeutics","volume":"27","author":"Gonzales","year":"2016","journal-title":"Vet Dermatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"CD013128","DOI":"10.1002\/14651858.CD013128.pub2","article-title":"Interventions for chronic pruritus of unknown origin","volume":"1","author":"Andrade","year":"2020","journal-title":"Cochrane Database Syst Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coph.2018.11.007","article-title":"Current treatment strategies in refractory chronic pruritus","volume":"46","author":"Pereira","year":"2019","journal-title":"Curr Opin Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/all.13239","article-title":"Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis","volume":"73","author":"Furue","year":"2018","journal-title":"Allergy."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e0161877","DOI":"10.1371\/journal.pone.0161877","article-title":"IL-31-driven skin remodeling involves epidermal cell proliferation and thickening that lead to impaired skin-barrier function","volume":"11","author":"Singh","year":"2016","journal-title":"PLoS ONE."},{"key":"B14","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jaci.2017.10.045","article-title":"IL-31: a new key player in dermatology and beyond","volume":"141","author":"Bagci","year":"2018","journal-title":"J Allergy Clin Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"S1081","DOI":"10.1016\/j.anai.2020.05.028","article-title":"New and emerging treatments for inflammatory itch","volume":"1","author":"Erickson","year":"2020","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1159\/000484406","article-title":"Emerging treatment options in atopic dermatitis: systemic therapies","volume":"233","author":"Nygaard","year":"2017","journal-title":"Dermatology."},{"key":"B17","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2500\/aap.2017.38.4080","article-title":"Interleukin 31 and skin diseases: a systematic review","volume":"38","author":"Gangemi","year":"2017","journal-title":"Allergy Asthma Proc."},{"key":"B18","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/exd.13533","article-title":"Interleukin-31 and interleukin-31 receptor: new therapeutic targets for atopic dermatitis","volume":"27","author":"Nakashima","year":"2018","journal-title":"Exp Dermatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.3390\/ijms18071485","article-title":"Inflammatory and noninflammatory itch: implications in pathophysiology-directed treatments","volume":"18","author":"Wong","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.08.035","article-title":"The characteristics and impact of pruritus in adult dermatologic patients: a prospective, cross-sectional study","author":"Hawro","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1001\/archdermatol.2011.178","article-title":"The impact of pruritus on quality of life: the skin equivalent of pain","volume":"147","author":"Kini","year":"2011","journal-title":"Arch Dermatol."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.08.020","article-title":"Health-related quality of life and economic burden of chronic pruritus","author":"Whang","year":"2020","journal-title":"J Invest Dermatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","article-title":"Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ijd.14081","article-title":"Itch and psyche: psychiatric aspects of pruritus","volume":"58","author":"Jafferany","year":"2019","journal-title":"Int J Dermatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.clindermatol.2017.01.008","article-title":"Psychiatric disorders and pruritus","volume":"35","author":"Lee","year":"2017","journal-title":"Clin Dermatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e13606","DOI":"10.1111\/dth.13606","article-title":"When life is an itch: what harms, helps, and heals from the patients' perspective? Differences and similarities among skin diseases","volume":"33","author":"Chee","year":"2020","journal-title":"Dermatol Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00403-019-01998-7","article-title":"Pruritus and sleep disturbances in patients with psoriasis","volume":"312","author":"Hawro","year":"2020","journal-title":"Arch Dermatol Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e190025","DOI":"10.1001\/jamapediatrics.2019.0025","article-title":"Association of atopic dermatitis with sleep quality in children","volume":"173","author":"Ramirez","year":"2019","journal-title":"JAMA Pediatr."},{"key":"B29","doi-asserted-by":"publisher","first-page":"109637","DOI":"10.1016\/j.mehy.2020.109637","article-title":"Sleep disturbance and atopic dermatitis: a bidirectional relationship?","volume":"140","author":"Xerfan","year":"2020","journal-title":"Med Hypotheses."},{"key":"B30","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jaad.2020.08.059","article-title":"Sleep disturbance in adults with chronic pruritic dermatoses is associated with increased C-reactive protein levels","volume":"84","author":"Patel","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jid.2019.07.711","article-title":"The annual direct and indirect health care costs for patients with chronic pruritus and their determining factors","volume":"140","author":"Luk","year":"2020","journal-title":"J Invest Dermatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.29262\/ram.v67i1.700","article-title":"[The annual cost of medical care for patients with moderate to severe atopic dermatitis in Mexico","volume":"67","author":"Guevara-Sangines","year":"2020","journal-title":"A multicenter study] (In Spanish). Rev Alerg Mex."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.1002","article-title":"Emergency department utilization by patients with prurigo nodularis in the United States","author":"Whang","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/medicines6030088","article-title":"Inpatient burden of prurigo nodularis in the United States","volume":"6","author":"Whang","year":"2019","journal-title":"Medicines."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3389\/fimmu.2019.01383","article-title":"Role of the pruritic cytokine IL-31 in autoimmune skin diseases","volume":"10","author":"Gibbs","year":"2019","journal-title":"Front Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/exd.12587","article-title":"Repeated administration of IL-31 upregulates IL-31 receptor A (IL-31RA) in dorsal root ganglia and causes severe itch-associated scratching behaviour in mice","volume":"24","author":"Arai","year":"2015","journal-title":"Exp Dermatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1600-0625.2008.00766.x","article-title":"Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC\/Nga mice: a model of atopic dermatitis","volume":"18","author":"Grimstad","year":"2009","journal-title":"Exp Dermatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"5049","DOI":"10.1111\/bph.12823","article-title":"Anti-IL-31 receptor antibody is shown to be a potential therapeutic option for treating itch and dermatitis in mice","volume":"171","author":"Kasutani","year":"2014","journal-title":"Br J Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2500\/aap.2020.41.190016","article-title":"Correlation of serum interleukin-31 with pruritus and blood eosinophil markers in children with atopic dermatitis","volume":"41","author":"Byeon","year":"2020","journal-title":"Allergy Asthma Proc."},{"key":"B40","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/j.1468-3083.2010.03794.x","article-title":"Serum measurement of interleukin-31 (IL-31) in paediatric atopic dermatitis: elevated levels correlate with severity scoring","volume":"25","author":"Ezzat","year":"2011","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"124","DOI":"10.11817\/j.issn.1672-7347.2018.02.003","article-title":"Serum interleukin-31 level and pruritus in atopic dermatitis: a meta-analysis","volume":"43","author":"Lu","year":"2018","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban."},{"key":"B42","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1684\/ejd.2011.1470","article-title":"Effects of cyclosporine on pruritus and serum IL-31 levels in patients with atopic dermatitis","volume":"21","author":"Otsuka","year":"2011","journal-title":"Eur J Dermatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1080\/09546634.2017.1290205","article-title":"Interleukin-31 pathway and its role in atopic dermatitis: a systematic review","volume":"28","author":"Saleem","year":"2017","journal-title":"J Dermatol Treat."},{"key":"B44","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","article-title":"A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1","volume":"133","author":"Cevikbas","year":"2014","journal-title":"J Allergy Clin Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaci.2005.10.046","article-title":"IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis","volume":"117","author":"Bilsborough","year":"2006","journal-title":"J Allergy Clin Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2340\/00015555-2774","article-title":"Chronic prurigo of nodular type: a review","volume":"98","author":"Zeidler","year":"2018","journal-title":"Acta Derm Venereol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","article-title":"IL-31: a new link between T cells and pruritus in atopic skin inflammation","volume":"117","author":"Sonkoly","year":"2006","journal-title":"J Allergy Clin Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA."},{"key":"B49","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00403-012-1293-6","article-title":"Narrow band ultraviolet B irradiations cause alteration in interleukin-31 serum level in psoriatic patients","volume":"305","author":"Narbutt","year":"2013","journal-title":"Arch Dermatol Res."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16563","article-title":"Identification of a TH 2-high psoriasis cluster based on skin biomarker analysis in a Chinese psoriasis population","author":"Chen","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jaci.2006.07.015","article-title":"Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis","volume":"118","author":"Neis","year":"2006","journal-title":"J Allergy Clin Immunol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"426","DOI":"10.5114\/pdia.2015.56097","article-title":"Itching sensation in psoriatic patients and its relation to body mass index and IL-17 and IL-31 concentrations","volume":"32","author":"Czarnecka-Operacz","year":"2015","journal-title":"Postepy Dermatol Alergol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1159\/000509281","article-title":"Pathogenesis and therapy of primary cutaneous T-cell lymphoma: Collegium Internationale Allergologicum (CIA) update 2020","volume":"181","author":"Bobrowicz","year":"2020","journal-title":"Int Arch Allergy Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"894","DOI":"10.2340\/00015555-2417","article-title":"Cutaneous T-cell lymphoma and pruritus: the expression of IL-31 and its receptors in the skin","volume":"96","author":"Nattkemper","year":"2016","journal-title":"Acta Derm Venereol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"282","DOI":"10.2340\/00015555-1345","article-title":"Serum IL-31 levels are increased in patients with cutaneous T-cell lymphoma","volume":"92","author":"Ohmatsu","year":"2012","journal-title":"Acta Derm Venereol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00403-014-1527-x","article-title":"Analysis of the IL-31 pathway in Mycosis fungoides and Sezary syndrome","volume":"307","author":"Mobs","year":"2015","journal-title":"Arch Dermatol Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1038\/jid.2013.227","article-title":"IL-31 is produced by the malignant T-cell population in cutaneous T-cell lymphoma and correlates with CTCL pruritus","volume":"133","author":"Singer","year":"2013","journal-title":"J Invest Dermatol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2340\/00015555-1958","article-title":"Il-31 does not correlate to pruritus related to early stage cutaneous T-cell lymphomas but is involved in pathogenesis of the disease","volume":"95","author":"Malek","year":"2015","journal-title":"Acta Derm Venereol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"319","DOI":"10.5114\/ada.2020.96260","article-title":"The ambiguous pruritogenic role of interleukin-31 in cutaneous T-cell lymphomas in comparison to atopic dermatitis: a review","volume":"37","author":"Olszewska","year":"2020","journal-title":"Postepy Dermatol Alergol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000489161","article-title":"Chronic prurigo: an unusual presentation of Hodgkin lymphoma","volume":"10","author":"Dumont","year":"2018","journal-title":"Case Rep Dermatol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"85263","DOI":"10.18632\/oncotarget.19665","article-title":"Interleukin-31 and thymic stromal lymphopoietin expression in plasma and lymph node from Hodgkin lymphoma patients","volume":"8","author":"Ferretti","year":"2017","journal-title":"Oncotarget."},{"key":"B62","doi-asserted-by":"publisher","first-page":"47","DOI":"10.14740\/jh499","article-title":"Plasma factors for the differentiation of Hodgkin's lymphoma and diffused large B cell lymphoma and for monitoring remission","volume":"8","author":"Zeng","year":"2019","journal-title":"J Hematol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"644","DOI":"10.5301\/jn.5000039","article-title":"Uremic pruritus","volume":"25","author":"Kfoury","year":"2012","journal-title":"J Nephrol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/ki.2013.454","article-title":"Uremic pruritus","volume":"87","author":"Mettang","year":"2015","journal-title":"Kidney Int."},{"key":"B65","doi-asserted-by":"publisher","first-page":"155369","DOI":"10.1016\/j.cyto.2020.155369","article-title":"Elevated interleukin 31 serum levels in hemodialysis patients are associated with uremic pruritus","volume":"138","author":"Oweis","year":"2020","journal-title":"Cytokine"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.jaad.2014.08.004","article-title":"Interleukin-31 is associated with uremic pruritus in patients receiving hemodialysis","volume":"71","author":"Ko","year":"2014","journal-title":"J Am Acad Dermatol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1159\/000440829","article-title":"Pathogenesis and management of pruritus in PBC and PSC","volume":"2","author":"Kremer","year":"2015","journal-title":"Dig Dis."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1080\/14767058.2016.1205025","article-title":"Interleukin 31 is involved in intrahepatic cholestasis of pregnancy","volume":"30","author":"Basile","year":"2017","journal-title":"J Matern Fetal Neonatal Med."},{"key":"B69","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1089\/vim.2014.0142","article-title":"Elevated TGF-beta1\/IL-31 pathway is associated with the disease severity of hepatitis B virus-related liver cirrhosis","volume":"28","author":"Ming","year":"2015","journal-title":"Viral Immunol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/cea.12875","article-title":"Human basophils are a source of - and are differentially activated by - IL-31","volume":"47","author":"Raap","year":"2017","journal-title":"Clin Exp Allergy."},{"key":"B71","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/j.1600-0625.2010.01067.x","article-title":"Increased levels of serum IL-31 in chronic spontaneous urticaria","volume":"19","author":"Raap","year":"2010","journal-title":"Exp Dermatol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"766","DOI":"10.2340\/00015555-2951","article-title":"Eosinophils are a major source of interleukin-31 in bullous pemphigoid","volume":"98","author":"R\u00fcdrich","year":"2018","journal-title":"Acta Derm Venereol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jdermsci.2017.07.019","article-title":"Elevated IL-31 serum levels in bullous pemphigoid patients correlate with eosinophil numbers and are associated with BP180-IgE","volume":"87","author":"Salz","year":"2017","journal-title":"J Dermatol Sci."},{"key":"B74","doi-asserted-by":"publisher","first-page":"5965492","DOI":"10.1155\/2017\/5965492","article-title":"The role of interleukin-31 in pathogenesis of itch and its intensity in a course of bullous pemphigoid and dermatitis herpetiformis","volume":"2017","author":"Kulczycka-Siennicka","year":"2017","journal-title":"Biomed Res Int."},{"key":"B75","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1111\/jdv.16730","article-title":"Increased expression of in situ IL-31RA and circulating CXCL8 and CCL2 in pemphigus herpetiformis suggests participation of the IL-31 family in the pathogenesis of the disease","volume":"34","author":"Morais","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"810","DOI":"10.12688\/f1000research.13499.1","article-title":"Recent advances in understanding and managing contact dermatitis","volume":"7","author":"Martin","year":"2018","journal-title":"F1000Res."},{"key":"B77","first-page":"156","article-title":"IL-31 and IL-33 circulating levels in allergic contact dermatitis","volume":"47","author":"Guarneri","year":"2015","journal-title":"Eur Ann Allergy Clin Immunol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"6639","DOI":"10.1038\/s41598-018-25094-4","article-title":"IL-31 is crucial for induction of pruritus, but not inflammation, in contact hypersensitivity","volume":"8","author":"Takamori","year":"2018","journal-title":"Sci Rep."},{"key":"B79","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jaad.2019.06.1309","article-title":"Dermatomyositis: clinical features and pathogenesis","volume":"82","author":"Dewane","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1365-2230.2004.01510.x","article-title":"Pruritus in adult dermatomyositis","volume":"29","author":"Shirani","year":"2004","journal-title":"Clin Exp Dermatol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/bjd.16498","article-title":"Itch in dermatomyositis: the role of increased skin interleukin-31","volume":"179","author":"Kim","year":"2018","journal-title":"Br J Dermatol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.jaad.2019.06.038","article-title":"Chronic pruritus of unknown origin (CPUO): uniform nomenclature and diagnosis as a pathway to standardized understanding and treatment","volume":"81","author":"Kim","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"854747","DOI":"10.1155\/2015\/854747","article-title":"IL-31 is overexpressed in lichen planus but its level does not correlate with pruritus severity","volume":"2015","author":"Welz-Kubiak","year":"2015","journal-title":"J Immunol Res."},{"key":"B84","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2340\/00015555-1829","article-title":"A Th2 cytokine interleukin-31 signature in a case of sporadic lichen amyloidosis","volume":"95","author":"Dousset","year":"2015","journal-title":"Acta Derm Venereol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1111\/bjd.14391","article-title":"Pathophysiology of pruritus in primary localized cutaneous amyloidosis","volume":"174","author":"Tey","year":"2016","journal-title":"Br J Dermatol."},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.23313","article-title":"Fractional carbon dioxide laser is effective in amelioration of pruritus in primary cutaneous amyloidosis: a clinical and biochemical study","author":"Fawzi","year":"2020","journal-title":"Lasers Surg Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.jid.2019.09.012","article-title":"Mechanisms of itch in stasis dermatitis: significant role of IL-31 from macrophages","volume":"140","author":"Hashimoto","year":"2020","journal-title":"J Invest Dermatol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1093\/rheumatology\/keaa195","article-title":"Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in scleroderma","volume":"59","author":"Yaseen","year":"2020","journal-title":"Rheumatology."},{"key":"B89","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.immuni.2020.06.023","article-title":"The cytokine TGF-beta induces interleukin-31 expression from dermal dendritic cells to activate sensory neurons and stimulate wound itching","volume":"53","author":"Xu","year":"2020","journal-title":"Immunity."},{"key":"B90","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1089\/jir.2007.0057","article-title":"Regulated expression of the IL-31 receptor in bronchial and alveolar epithelial cells, pulmonary fibroblasts, and pulmonary macrophages","volume":"28","author":"Jawa","year":"2008","journal-title":"J Interferon Cytokine Res."},{"key":"B91","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/j.1365-2567.2007.02668.x","article-title":"Interleukin-31 induces cytokine and chemokine production from human bronchial epithelial cells through activation of mitogen-activated protein kinase signalling pathways: Implications for the allergic response","volume":"122","author":"Ip","year":"2007","journal-title":"Immunology."},{"key":"B92","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1398-9995.2007.01566.x","article-title":"SCF and IL-31 rather than IL-17 and BAFF are potential indicators in patients with allergic asthma","volume":"63","author":"Lei","year":"2008","journal-title":"Allergy."},{"key":"B93","doi-asserted-by":"publisher","first-page":"22835","DOI":"10.1038\/srep22835","article-title":"Interleukin-31 expression and relation to disease severity in human asthma","volume":"6","author":"Lai","year":"2016","journal-title":"Sci Rep."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1136\/gut.2006.118679","article-title":"Interleukin 31 mediates MAP kinase and STAT1\/3 activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease","volume":"56","author":"Dambacher","year":"2007","journal-title":"Gut."},{"key":"B95","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1080\/14728222.2019.1677608","article-title":"Oncostatin M as a new diagnostic, prognostic and therapeutic target in inflammatory bowel disease (IBD)","volume":"23","author":"Verstockt","year":"2019","journal-title":"Expert Opin Ther Targets."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.3390\/ijms21041239","article-title":"IL-33\/IL-31 axis in osteoporosis","volume":"21","author":"De Martinis","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B97","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12865-015-0125-9","article-title":"Increased levels of interleukin 31 (IL-31) in osteoporosis","volume":"16","author":"Ginaldi","year":"2015","journal-title":"BMC Immunol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.3389\/fimmu.2019.02666","article-title":"Commentary: circulatory pattern of cytokines, adipokines and bone markers in postmenopausal women with low BMD","volume":"10","author":"Mannucci","year":"2019","journal-title":"Front Immunol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jaad.2017.12.077","article-title":"An assessment of the use of antihistamines in the management of atopic dermatitis","volume":"79","author":"He","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jaci.2019.06.016","article-title":"Pruritus in allergy and immunology","volume":"144","author":"Yang","year":"2019","journal-title":"J Allergy Clin Immunol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1111\/exd.14007","article-title":"Treatments for chronic pruritus outside of the box","volume":"28","author":"Metz","year":"2019","journal-title":"Exp Dermatol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"adv00028","DOI":"10.2340\/00015555-3348","article-title":"Challenges in clinical research and care in pruritus","volume":"100","author":"Pereira","year":"2020","journal-title":"Acta Derm Venereol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1056\/NEJMoa1917006","article-title":"Trial of nemolizumab and topical agents for atopic dermatitis with pruritus","volume":"383","author":"Kabashima","year":"2020","journal-title":"N Engl J Med."},{"key":"B104","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa1908316","article-title":"Trial of nemolizumab in moderate-to-severe prurigo nodularis","volume":"382","author":"St\u00e4nder","year":"2020","journal-title":"N Engl J Med."},{"key":"B105","unstructured":"Lexington, MAKiniksa Pharmaceuticals Corp2020"},{"key":"B106","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/exd.13236","article-title":"Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody","volume":"27","author":"Oyama","year":"2018","journal-title":"Exp Dermatol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.vetimm.2009.03.014","article-title":"Molecular cloning of canine interleukin-31 and its expression in various tissues","volume":"131","author":"Mizuno","year":"2009","journal-title":"Vet Immunol Immunopathol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1365-3164.2012.01098.x","article-title":"Interleukin-31: Its role in canine pruritus and naturally occurring canine atopic dermatitis","volume":"24","author":"Gonzales","year":"2013","journal-title":"Vet Dermatol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/vde.12364","article-title":"A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis","volume":"27","author":"Michels","year":"2016","journal-title":"Vet Dermatol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/vde.12682","article-title":"A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA","volume":"29","author":"Souza","year":"2018","journal-title":"Vet Dermatol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"191","DOI":"10.24425\/pjvs.2020.132765","article-title":"Evaluation of the clinical efficiency of lokivetmab in client privately owned atopic dogs - multicenter study","volume":"23","author":"Szczepanik","year":"2020","journal-title":"Pol J Vet Sci."},{"key":"B112","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/vde.12702","article-title":"Lokivetmab therapy for pruritus in a dog with cutaneous mastocytosis","volume":"30","author":"Meichner","year":"2019","journal-title":"Vet Dermatol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/bjd.14207","article-title":"The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study","volume":"174","author":"Nemoto","year":"2016","journal-title":"Br J Dermatol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.jaci.2018.03.018","article-title":"Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study","volume":"142","author":"Kabashima","year":"2018","journal-title":"J Allergy Clin Immunol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti-interleukin-31 receptor A antibody for atopic dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N Engl J Med."},{"key":"B116","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","article-title":"Phase 2b randomized study of nemolizumab in adults with moderate-severe atopic dermatitis and severe pruritus","volume":"145","author":"Silverberg","year":"2020","journal-title":"J Allergy Clin Immunol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/1346-8138.14934","article-title":"Nemolizumab in moderate to severe atopic dermatitis: an exploratory analysis of work productivity and activity impairment in a randomized phase II study","volume":"46","author":"Mihara","year":"2019","journal-title":"J Dermatol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s40257-016-0215-3","article-title":"Itch in the general internal medicine setting: a cross-sectional study of prevalence and quality-of-life effects","volume":"17","author":"Silverberg","year":"2016","journal-title":"Am J Clin Dermatol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.alit.2016.12.002","article-title":"Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies","volume":"66","author":"Furue","year":"2017","journal-title":"Allergol Int."},{"key":"B120","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.anai.2020.08.016","article-title":"New treatments in atopic dermatitis","volume":"126","author":"Puar","year":"2021","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40257-020-00534-y","article-title":"Emerging therapeutic options for chronic pruritus","volume":"21","author":"Reszke","year":"2020","journal-title":"Am J Clin Dermatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.638325\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T18:09:40Z","timestamp":1613239780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.638325\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,12]]},"references-count":121,"alternative-id":["10.3389\/fmed.2021.638325"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.638325","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,12]]},"article-number":"638325"}}